



Special Interest Group (SIG) on Drug Delivery and Manufacturing (DDM) Annual Report 2021

- SIG on DDM collaborated with Academy of Pharmaceutical Scientists, APS, on FIP Digital Event Plan (DEP), January 26, 2021. Tetsuya was a moderator for the event entitled “Manufacturing Classification System for oral solid dosage forms: Good in Theory and in Practice”.
- Prof. Tetsuya Ozeki continued the FIP YPG Mentoring Program activities from January to May 1st, the rest of the program. It was a weekly lecture on DDS and pharmaceutical science. He got a certificate of completion of FIP YPG Mentorship Program 2020-2021 as a mentor from the SIG DDM. Aliasger Salem provided some mentoring advice to FIP YPG members seeking advice on applying to graduate school.
- Prof. Tetsuya Ozeki and Aliasger Salem reported that the SIG leadership contributed to the 20-year anniversary of YPG by sending bios and content of the SIG’s work. The SIG also contributed to the YPG survey and introduced the survey to all members of the SIG by sending an email.
- Pediatric Formulation Focus Group (PFFG) was set up to be led by Dr Hala Fadda (USA). The first zoom meeting was held with FIP Hospital and Community Pharmacy sections, DDM and Academy of Pharmaceutical Sciences and Technology Japan (APSTJ) on 5th Jan 2021, 12 pm CET. We discussed the purpose of this FG, future activities, and international relations. FG also had a zoom mtg on 27th May 2021, 1 pm CET and discussed the global harmonization of oral extemporaneous pediatric preparation practices.

PFFG has expanded to include 30 pharmacists, scientists and academics from across the globe; spanning all the WHO regions. A survey to identify current oral extemporaneous pediatric compounding practices, challenges and needs in different geographic regions was developed, piloted, approved by ethics institution review board and translated into nine different languages. The survey is currently in progress and receiving extensive interest from pharmacists who are expressing the need for national and global efforts to standardize and improve feasibility of oral extemporaneous compounding.

[PFFG web page](#) was developed to promote awareness of the initiative and engagement. Patient centric product design for paediatrics was presented by Dr Hala Fadda at the FIP Development Goals Digital Programme: Medicines Expertise, on 10th Dec 2021.

The next step is to develop best strategies and training for oral extemporaneous pediatric compounding through the commitment of PFFG members and engagement with stakeholders. FIP strives to bridge education, science and practice and is therefore in the best position to achieve a global and coordinated effort to address the challenges in pediatric medicines.

Goals in 2022:

- Goal #1:
The DDM leadership team to engage more effectively with colleagues from various BPP Sections in joint programming activities to underline invaluable relationship between clinical and practical outcomes and scientifically designed drug delivery and manufacturing.
- Goal #2:
To disseminate knowledge and facilitate networking between drug delivery and manufacturing professionals worldwide through webinars, opinion papers or reports
- Goal #3:
PFFG to publish results of pediatric extemporaneous compounding survey and engage with stakeholders to address the challenges identified in the survey